Cargando…
Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer
Optimal induction strategy in highly sensitized kidney transplant recipients (KTRs) is still a matter of debate. The place of therapies, such as plasma exchange and rituximab, with potential side effects and high cost, is not clearly established. We compared two induction strategies with (intensive)...
Autores principales: | Mohamadou, Inna, Matignon, Marie, Malard, Stéphanie, Lombardi, Yannis, Buob, David, Moktefi, Anissa, Jamme, Matthieu, Ouali, Nacera, Rafat, Cedric, François, Hélène, Petit-Hoang, Camille, Rondeau, Eric, Mesnard, Laurent, Grimbert, Philippe, Taupin, Jean-Luc, Luque, Yosu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088221/ https://www.ncbi.nlm.nih.gov/pubmed/37056357 http://dx.doi.org/10.3389/ti.2023.10844 |
Ejemplares similares
-
Immunoadsorption-Based HLA Desensitization in Patients Awaiting Deceased Donor Kidney Transplantation: An Interventional, Non-Randomised, Single Cohort Study
por: Bureau, Côme, et al.
Publicado: (2023) -
Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023) -
COVID-19-associated acute kidney injury: after the tubule and the glomerulus, now the vessel?
por: Mayet, Valentin, et al.
Publicado: (2020) -
Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy
por: Morel, Antoine, et al.
Publicado: (2022) -
Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines
por: Couzi, Lionel, et al.
Publicado: (2023)